- Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists
- The lead candidate, HTL0022562, has advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials
- Sosei Heptares will receive an upfront payment of US$10 million, plus downstream payments of up to US$370 million, plus tiered royalties
PR Newswire
TOKYO and CAMBRIDGE, England, Dec. 1, 2020